The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks edge higher ahead of US jobs report

Fri, 02nd Jul 2021 12:18

(Alliance News) - Stock prices in London were slightly higher at midday on Friday as investors look ahead trepidatiously to the US jobs report for June at 1330 BST, while GlaxoSmithKline leapt to the defence of its under-fire chief executive.

Economists expect US nonfarm payrolls to rise by 690,000 in June and the unemployment rate to edge down to 5.7% from 5.8% in May, according to consensus cited by FXStreet.

The FTSE 100 index was up 10.64 points, or 0.2%, at 7,135.80. The mid-cap FTSE 250 index was up 104.41 points, or 0.5%, at 22,727.18. The AIM All-Share index was up 4.81 points, or 0.4%, at 1,264.52.

The Cboe UK 100 index was up 0.1% at 709.80. The Cboe 250 was up 0.6% at 20,444.73, and the Cboe Small Companies was up 0.1% at 15,426.10.

In Paris, the CAC 40 was up 0.2%, while Frankfurt's DAX 30 was up 0.5%.

"The FTSE is edging higher, shrugging off rising Covid cases as homebuilders lead the charge. Jefferies is maintaining its positive stance over UK homebuilders, keeping the likes of Taylor Wimpey and Barratt Developments buoyant," commented Oanda Markets analyst Sophie Griffiths.

Barratt Developments was up 2.0% after Jefferies upgraded the housebuilder to Buy from Hold.

Peers Taylor Wimpey, Persimmon and Berkeley were up 1.0%, 0.8% and 0.3%, respectively, as Jefferies took an upbeat stance on the sector, despite the expiry of the UK government's stamp duty holiday on Wednesday.

In the FTSE 250, Bellway was up 2.5% after Jefferies raised the Newcastle-based housebuilder to Buy from Hold.

New York stock market futures were pointed marginally higher ahead of the US jobs numbers.

On the corporate front, Johnson & Johnson was 0.1% higher in pre-market trade in New York. The drugmaker said new data has shown its single-shot Covid vaccine generates a "strong, persistent activity" against the India, or Delta, variant.

The data showed that the J&J's Covid-19 vaccine elicited "neutralising antibody activity" against the Delta variant at an even higher level than what was recently observed for the Beta variant in South Africa where high efficacy against severe and critical disease was demonstrated, J&J explained.

In the FTSE 100, Informa was the best performer, up 2.9%, after Berenberg raised the events and publishing company to Buy from Hold.

GlaxoSmithKline was up 0.1%. The drugmaker said Chief Executive Emma Walmsley is the right leader for the core pharmaceutical and vaccines business after the consumer division gets spun off, in response to a scathing open letter from activist investor Elliott Management Corp.

GSK is planning to spin off its consumer healthcare division, which includes toothpaste and over-the-counter medicines, from its pharmaceuticals and vaccines business, which it calls New GSK.

On Thursday, Elliott said it had built a significant stake in the London-based company, which has failed to realise its value after years of poor performance.

On Friday, the Brentford-based firm said its largest shareholders support its strategy and have confidence in its leadership.

At other end of the large-caps, Rightmove was down 1.0% after UBS downgraded the property portal to Neutral from Buy.

Sterling slipped after Bank of England Governor Andrew Bailey on Thursday said recent consumer price pressures should prove temporary.

The pound was quoted at USD1.3745 at midday on Friday, down from USD1.3775 at the London equities close Thursday and declining further from the GBP1.39 mark reached at the start of the week.

The euro stood at USD1.1825, lower from USD1.1851. Against the yen, the dollar was quoted at JPY111.50, little changed from JPY111.59.

Analysts at ActivTrades explained "The US dollar remains on the front foot during Friday trading, with the publication of the US nonfarm payrolls employment data just a few hours away. Having ended every trading session so far this week in the green, the greenback hit a fresh multi-month high this morning as the markets price in a positive employment data number, which in today's case will be on or above the consensus of 690,000.

"An encouraging number of new jobs created during the month of June will strengthen the case for earlier tapering of the ongoing monetary stimulus, offering more support to the greenback. Conversely, a figure falling short of expectations will diminish the scope for further dollar gains in the short-term."

Brent oil was quoted at USD75.80 a barrel on Friday at midday, up from USD75.52 at the London equities close Thursday. Gold was quoted at USD1,785.45 an ounce, higher against USD1,769.16 late Thursday.

Major oil-producing countries on Thursday failed to agree to boost output in August to meet growing demand and limit recent price rises, adjourning their meeting to Friday.

The 13 members of OPEC and 10 allies were expected to make a decision to continue to moderately increase output beyond July.

The OPEC+ grouping cut crude production after the pandemic sent oil prices crashing last year. But the group has slightly increased production since early May. Oil prices have recovered, this week reaching levels last seen in October 2018. OPEC members led by Saudi Arabia conferred Thursday via a teleconference.

But a subsequent technical meeting of OPEC members together with their 10 allies led by Russia failed to reach consensus, leading to discussions being postponed until Friday, according to an OPEC statement.

"The members of the oil cartel clashed yesterday, with the United Arab Emirates blocking the agreement until the baseline for its production cuts was adjusted. This forced the group to postpone the meeting, raising concerns about the supply of oil in the coming months. The impasse between the UAE and the rest of the group could mean that oil supply will not be increased at all under the current terms until April 2022, pushing oil prices even higher and contributing to the already concerning spike in inflation," said AvaTrade analyst Naeem Aslam.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.